Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Press Releases

5 Mar 2021

MEC signs RTO definitive agreement to acquire Albert Labs, a European psychedelic drug researcher & developer

Albert Labs leverages Real-World Evidence (RWE) studies across Europe to accelerate access to its proprietary psilocybin-based therapy for patients with urgent, unmet needs....

By Microdose

Press Releases

4 Mar 2021

February User Metrics for PSYC’s Psychedelic Spotlight Platform Reflect Impressive Growth Rate of 40%

Growth of Psychedelic Spotlight Creates Potential Revenue Opportunities for PSYC LAS VEGAS, NV, March 04, 2021 (GLOBE NEWSWIRE) — Global Trac Solutions, Inc....

By Microdose

Press Releases

4 Mar 2021

Tryp Therapeutics Announces Application to List on OTCQB

La Jolla, California–(Newsfile Corp....

By Microdose

Press Releases

4 Mar 2021

MagicMed Industries Announces Collaboration with Artificial Intelligence Thought Leaders and the Launch of PsyAI™

CALGARY, AB, March 4, 2021 /CNW/ – MagicMed Industries Inc....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

4 Mar 2021

Regulatory approvals place Numinus lab at the forefront of global psychedelics research

Numinus Bioscience adds Ketamine and LSD to licence to produce, assemble and sell a wide variety of psychedelic compounds VANCOUVER, BC, March 4, 2021 /CNW/ - Numinus Wellness Inc....

By Microdose

Press Releases

4 Mar 2021

Pure Extracts Submits Dealer’s Licence Application to Health Canada

VANCOUVER, British Columbia, March 04, 2021 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp....

By Microdose

Press Releases

3 Mar 2021

REPEAT – Pure Extracts Orders Over 30,000 Vape Cartridges in Preparation for Retail Distribution

VANCOUVER, British Columbia, March 03, 2021 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp....

By Microdose

Press Releases

3 Mar 2021

Ehave Inc. Files for KetaDash Trademark and to Uplist its Shares to the OTCQB

MIAMI, March 03, 2021 (GLOBE NEWSWIRE) — Ehave, Inc....

By Microdose

Press Releases

3 Mar 2021

Entheon Biomedical Announces Nancy Maher, Special Advisor of Data Science and Regulatory Affairs

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.